DNMT3A and acute myeloid leukemia: In the context of AML, Tang and colleagues reported that individuals with AML, or SKM-1 and K562 cell lines, with the FLT3 or DNMT3A mutations had higher expression levels of CD44v6 (in comparison with the patients without the mentioned mutations) (70).